Evidence supporting the use of: Polyunsaturated fatty acid
For the health condition: Congestive Heart Failure

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Polyunsaturated fatty acids (PUFAs), particularly the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have some scientific support for their use in congestive heart failure (CHF). Several clinical studies and meta-analyses have explored their effects on heart failure outcomes. The most notable is the GISSI-HF trial (2008), a large, randomized, placebo-controlled study involving over 6,000 patients with CHF. This trial demonstrated a small but statistically significant reduction in all-cause mortality and hospital admissions for cardiovascular reasons in patients receiving 1 gram per day of omega-3 PUFAs in addition to standard therapy. The proposed mechanisms include anti-inflammatory effects, anti-arrhythmic properties, and improvements in endothelial function. However, the magnitude of benefit observed is modest, and not all studies have shown consistent results. Some meta-analyses suggest that while omega-3 PUFA supplementation may have a beneficial effect on mortality and hospitalization, the clinical significance is limited. Guidelines such as those from the American Heart Association acknowledge the potential benefit but do not strongly recommend PUFAs as a primary therapy for CHF. In summary, there is scientific evidence supporting the adjunctive use of polyunsaturated fatty acids in CHF, but the overall effect size is small, and their use should not replace standard heart failure treatments. The evidence is rated as moderate (2 out of 5), reflecting limited but positive findings.

More about Polyunsaturated fatty acid
More about Congestive Heart Failure

Products containing Polyunsaturated fatty acid

We currently have no products on Vitabase that contain this ingredient.